Does the media favor IMNM or ACRS?

In the previous week, Aclaris Therapeutics had 7 more articles in the media than Immunome. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 7 mentions for Immunome. Aclaris Therapeutics' average media sentiment score of 1.31 beat Immunome's score of 0.93 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KOD or ACRS?

In the previous week, Aclaris Therapeutics had 9 more articles in the media than Kodiak Sciences. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 5 mentions for Kodiak Sciences. Aclaris Therapeutics' average media sentiment score of 1.31 beat Kodiak Sciences' score of 0.75 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACRS or ELVN?

In the previous week, Aclaris Therapeutics had 6 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 8 mentions for Enliven Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.31 beat Enliven Therapeutics' score of 0.38 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RARE or ACRS?

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 11 mentions for Ultragenyx Pharmaceutical. Aclaris Therapeutics' average media sentiment score of 1.31 beat Ultragenyx Pharmaceutical's score of 0.76 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ACRS or RXRX?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Recursion Pharmaceuticals and 14 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.31 beat Recursion Pharmaceuticals' score of 0.61 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Aclaris Therapeutics (ACRS) Competitors

$4.10 -0.20 (-4.65%)

Closing price 04:00 PM Eastern

Extended Trading

$4.11 +0.01 (+0.12%)

As of 06:35 PM Eastern

Compare

ACRS vs. IMNM, KOD, ELVN, RARE, and RXRX

Should you buy Aclaris Therapeutics stock or one of its competitors? MarketBeat compares Aclaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclaris Therapeutics include Immunome (IMNM), Kodiak Sciences (KOD), Enliven Therapeutics (ELVN), Ultragenyx Pharmaceutical (RARE), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry.

How does Aclaris Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Immunome has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Immunome's return on equity of -51.15% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

In the previous week, Aclaris Therapeutics had 7 more articles in the media than Immunome. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 7 mentions for Immunome. Aclaris Therapeutics' average media sentiment score of 1.31 beat Immunome's score of 0.93 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	296.34	-$212.39M	-$2.38	N/A
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A

44.6% of Immunome shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunome presently has a consensus price target of $33.17, indicating a potential upside of 82.64%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 180.49%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Immunome has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Immunome on 10 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Kodiak Sciences presently has a consensus target price of $42.14, indicating a potential upside of 34.17%. Aclaris Therapeutics has a consensus target price of $11.50, indicating a potential upside of 180.49%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aclaris Therapeutics had 9 more articles in the media than Kodiak Sciences. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 5 mentions for Kodiak Sciences. Aclaris Therapeutics' average media sentiment score of 1.31 beat Kodiak Sciences' score of 0.75 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Aclaris Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A

Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Summary

Aclaris Therapeutics beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Enliven Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Aclaris Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Enliven Therapeutics has a consensus price target of $61.50, suggesting a potential upside of 66.22%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Aclaris Therapeutics had 6 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 8 mentions for Enliven Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.31 beat Enliven Therapeutics' score of 0.38 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Enliven Therapeutics' return on equity of -21.04% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Aclaris Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aclaris Therapeutics beats Enliven Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Aclaris Therapeutics (NASDAQ:ACRS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Aclaris Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.36	-$575M	-$6.11	N/A
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 14 mentions for Aclaris Therapeutics and 11 mentions for Ultragenyx Pharmaceutical. Aclaris Therapeutics' average media sentiment score of 1.31 beat Ultragenyx Pharmaceutical's score of 0.76 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ultragenyx Pharmaceutical currently has a consensus target price of $59.56, suggesting a potential upside of 159.31%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 180.49%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Aclaris Therapeutics beats Ultragenyx Pharmaceutical on 12 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Recursion Pharmaceuticals?

Aclaris Therapeutics (NASDAQ:ACRS) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Recursion Pharmaceuticals and 14 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.31 beat Recursion Pharmaceuticals' score of 0.61 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Aclaris Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 180.49%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 166.45%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aclaris Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Aclaris Therapeutics has a net margin of -832.58% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Aclaris Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	73.13	-$64.92M	-$0.56	N/A
Recursion Pharmaceuticals	$74.68M	21.57	-$644.76M	-$1.20	N/A

Summary

Aclaris Therapeutics beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$600.55M	$2.94B	$6.41B	$11.71B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	N/A	17.80	24.46	23.62
Price / Sales	73.13	289.23	500.50	105.26
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	4.82	3.88	10.43	6.70
Net Income	-$64.92M	$75.85M	$3.56B	$337.26M
7 Day Performance	-7.24%	-1.87%	-1.39%	-1.41%
1 Month Performance	-16.84%	-6.20%	0.86%	1.15%
1 Year Performance	171.52%	12.60%	19.42%	22.61%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	3.336 of 5 stars	$4.10 -4.7%	$11.50 +180.5%	+188.6%	$600.55M	$7.83M	N/A	100	Positive News
IMNM Immunome	3.5998 of 5 stars	$20.78 -4.8%	$33.17 +59.6%	+98.4%	$2.35B	$6.94M	N/A	40	Insider Trade
KOD Kodiak Sciences	2.4445 of 5 stars	$36.91 +0.5%	$42.14 +14.2%	+648.4%	$2.31B	N/A	N/A	90
ELVN Enliven Therapeutics	2.789 of 5 stars	$37.51 -5.2%	$58.40 +55.7%	+77.5%	$2.28B	N/A	N/A	50	News Coverage Analyst Forecast Insider Trade
RARE Ultragenyx Pharmaceutical	2.8826 of 5 stars	$22.85 -4.6%	$59.56 +160.7%	-38.5%	$2.25B	$673M	N/A	1,371	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. IMNM, KOD, ELVN, RARE, and RXRX

How does Aclaris Therapeutics compare to Immunome?

Summary

How does Aclaris Therapeutics compare to Kodiak Sciences?

Summary

How does Aclaris Therapeutics compare to Enliven Therapeutics?

Summary

How does Aclaris Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Aclaris Therapeutics compare to Recursion Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. IMNM, KOD, ELVN, RARE, and RXRX

How does Aclaris Therapeutics compare to Immunome?

Is IMNM or ACRS more profitable?

Does the media favor IMNM or ACRS?

Which has preferable earnings & valuation, IMNM or ACRS?

Do institutionals & insiders have more ownership in IMNM or ACRS?

Do analysts prefer IMNM or ACRS?

Which has more risk & volatility, IMNM or ACRS?

Summary

How does Aclaris Therapeutics compare to Kodiak Sciences?

Do analysts rate KOD or ACRS?

Do insiders & institutionals have more ownership in KOD or ACRS?

Does the media favor KOD or ACRS?

Is KOD or ACRS more profitable?

Which has higher valuation and earnings, KOD or ACRS?

Which has more risk & volatility, KOD or ACRS?

Summary

How does Aclaris Therapeutics compare to Enliven Therapeutics?

Do analysts recommend ACRS or ELVN?

Does the media favor ACRS or ELVN?

Which has more volatility & risk, ACRS or ELVN?

Is ACRS or ELVN more profitable?

Which has preferable earnings & valuation, ACRS or ELVN?

Do institutionals & insiders hold more shares of ACRS or ELVN?

Summary

How does Aclaris Therapeutics compare to Ultragenyx Pharmaceutical?

Which has stronger valuation and earnings, RARE or ACRS?

Does the media favor RARE or ACRS?

Which has more risk & volatility, RARE or ACRS?

Is RARE or ACRS more profitable?

Do insiders & institutionals hold more shares of RARE or ACRS?

Do analysts prefer RARE or ACRS?

Summary

How does Aclaris Therapeutics compare to Recursion Pharmaceuticals?

Do insiders and institutionals hold more shares of ACRS or RXRX?

Does the media refer more to ACRS or RXRX?

Do analysts recommend ACRS or RXRX?

Which has more risk & volatility, ACRS or RXRX?

Is ACRS or RXRX more profitable?

Which has higher earnings and valuation, ACRS or RXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools